NPO 13Alternative Names: NPO-13
Latest Information Update: 22 May 2015
At a glance
- Originator Nihon Pharmaceutical
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastrointestinal disorders
Most Recent Events
- 22 May 2015 Nihon Pharmaceutical completed phase-II clinical trials in Gastrointestinal disorders (Diagnosis) in Japan (Intraluminal) (NCT02265939)
- 01 Oct 2014 Phase-II clinical trials in Gastrointestinal disorders (Diagnosis) in Japan (Intraluminal)